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Abstract
Background: Although dysnatremia has been reported to be correlated with mortality risk, this issue remains unresolved
in patients undergoing continuous renal replacement therapy (CRRT). Furthermore, it has not been determined whether
change in or correction of sodium is related to mortality risk in this subset.
Methods: A total of 569 patients were prospectively enrolled at the start of CRRT between May 2010 and September
2013. The patients were divided into 5 groups: normonatremia (135–145 mmol/L), mild hyponatremia
(131.1–134.9 mmol/L), moderate to severe hyponatremia (115.4–131.0 mmol/L), mild hypernatremia (145.1–148.4 mmol/L),
and moderate to severe hypernatremia (148.5–166.0 mmol/L). The non-linear relationship between sodium
and mortality was initially explored. Subsequently, the odds ratios (ORs) for 30-day mortality were calculated
after adjustment of multiple covariates.
Results: The relationship between baseline sodium and mortality was U-shaped. The mild hyponatremia, moderate to
severe hyponatremia, and moderate to severe hypernatremia groups had greater ORs for mortality (1.65, 1.91, and 2.32,
respectively) than the normonatremia group (all P values < 0.05). However, later sodium levels (24 and 72 h after CRRT)
did not predict 30-day mortality. Furthermore, the changes in sodium over 24 or 72 h, including the appropriate
correction of dysnatremia, did not show any relationships with mortality, irrespective of baseline sodium level.
Conclusions: Sodium level at the start of CRRT was a strong predictor of mortality. However, changes in sodium
level and the degree of sodium correction were not associated with the mortality risk in the patients with CRRT.
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Background
Both hyponatremia and hypernatremia are important
risk factors for high morbidity and mortality in several
clinical settings [1, 2]. However, reports have conflicted
about the dependent and independent relationships of
sodium with mortality. A relationship is plausible because
both hyponatremia and hypernatremia have adverse con-
sequences via their effects on the brain, heart, and other
organs [3, 4]. However, dysnatremia might be only a
marker of comorbidities, with deaths attributable mainly
to the severity of the diseases and not to dysnatremia itself
[5]. A recent review of hyponatremia cases concluded that
deaths were associated with the underlying illness, rather
than with the severity of hyponatremia [6]. Given the na-
ture of this issue, it is unclear whether the correction of
sodium can reduce the mortality risk. Most randomized
controlled trials of drugs for sodium correction have not
demonstrated a survival advantage [7]. Although these re-
sults have not excluded the need for sodium correction, it
is necessary to address whether sodium correction alone
can reduce mortality. A well-designed observational study
could be helpful because randomized controlled trials for
this issue are not feasible.
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Continuous renal replacement therapy (CRRT) is increas-
ingly used in severe acute kidney injury (AKI), because it
can easily control biochemical imbalances due to AKI [8].
The presence of AKI or comorbidities hinders the effective-
ness of conventional fluid or drug management, but CRRT
can overcome these difficulties and achieve normonatremia.
Here, we first addressed how sodium levels predict mortal-
ity in a prospective cohort of patients receiving CRRT, in
whom the control of dysnatremia was extremely difficult
with conventional treatment alone. Whether sodium cor-
rection is independently associated with reduced mortality
in comorbid conditions was also addressed.
Methods
Participants and data collection
Data on patients undergoing CRRT were obtained pro-
spectively from a cohort from the tertiary referral center
(Seoul National University Hospital). The inclusion cri-
teria were as follows: CRRT was needed due to severe
AKI; and the patient’s age was 18 years old or older.
Accordingly, a total of 669 patients were enrolled at the
start of CRRT from May 2010 to September 2013. All of
the patients who participated in the present study pro-
vided informed consent and agreed with serial examin-
ation of serum sodium in adherence to the study
protocol. We excluded patients who were previously
diagnosed with end-stage renal disease or who received
dialysis before enrollment (n = 97). If the patients under-
went CRRT more than once (n = 3), only the first experi-
ence was counted as a single case. Consequently, 569
patients were analyzed for the present study. Flow
diagram for this process is shown in Additional file 1.
Clinical parameters, such as age, sex, weight, cause of
AKI, dialysis dose, the need for mechanical ventilation, the
use of vasoactive drugs, and underlying chronic kidney dis-
ease, were recorded at the start of CRRT. The causes of
AKI were divided into sepsis, surgery, nephrotoxin, and
others. Information on comorbidities was collected and was
presented as Charlson Comorbidity Index [9]. The Acute
Physiology and Chronic Health Evaluation (APACHE) ІІ
score was calculated to quantitatively assess each patient’s
status [10]. Serum sodium, creatinine, and albumin were
measured (Toshiba-200FR, Toshiba, Tokyo, Japan), and the
urine output data during the first 2 h of CRRT were re-
corded. Serum sodium was additionally measured at 24 and
72 h after CRRT. Fluid balance before evaluation of later
sodium levels (24 and 72 h) was monitored and expressed
as follows: fluid balance = total input – total output.
There were no missing data for any of the variables.
Corrected sodium values for serum glucose were used
in the study analyses, based on the following formula:
corrected sodium =measured sodium + 0.016 × (serum
glucose – 100) [11]. The onsets of dysnatremia were
presented as acute (duration < 48 h), chronic (≥ 48 h), or
unknown duration. If dysnatremia was identified, it was
treated using CRRT with diluted or concentrated substitu-
tion fluid to control the speed of correction [12, 13].
The primary outcome was 30-day all-cause mortality
after starting CRRT. The mortality data were obtained
from the national database of Statistics Korea; all Koreans
have a resident registration number and death events
are recorded and stored at a national level.
The study protocol complies with the Declaration of
Helsinki and received full approval from the institutional
review board at the Seoul National University Hospital
(no. 1309-018-518). No extramural funding was used to
support this work. The authors are solely responsible for
the design and conduct of this study, all study analyses
and drafting and editing of the paper.
Statistical analysis
All of the analyses and calculations were performed using
STATA software (version 12.0, StataCorp LP, College
Station, Texas, USA). The data are presented as the
mean ± standard deviations for continuous variables and as
proportions for categorical variables. Based on variable dis-
tributions using histograms, the variables with non-normal
distributions are expressed as the median (interquartile
ranges). The chi-squared test was used to compare the cat-
egorical variables. Comparisons between normally distrib-
uted continuous variables were performed using an analysis
of variance or a post-hoc analysis of least significant differ-
ence, according to the number of comparison groups.
Comparisons between non-normally distributed continuous
variables were performed by either the Kruskal-Wallis test
or the Mann–Whitney U test, depending on the number of
comparison groups. The dose–response relationship (in
particular, the non-linear relationship) between sodium and
mortality was initially explored by a restricted cubic spline
analysis. Due to the U-shaped relationship, we divided
the patients into five groups as follows: normonatremia
(135–145 mmol/L), mild hyponatremia, moderate to severe
hyponatremia, mild hypernatremia, and moderate to severe
hypernatremia. The mild and moderate to severe dysnatre-
mia groups were determined based on the median sodium
value within each hypo- and hyper-natremia group. Sur-
vival curves were drawn using the Kaplan-Meier method.
To compare survival curves between groups, the log-rank
test was initially applied. The odds ratios (ORs) and 95 %
confidence intervals (CIs) for 30-day mortality were calcu-
lated using the logistic regression model after adjustment of
all covariates (as provided in Table 1). A P value less than
0.05 was considered significant.
Results
Baseline characteristics
The baseline characteristics of the patients are shown
and compared between groups with respect to serum
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sodium level in Table 1. For the 569 subjects, the mean
age was 63 years. Except for one Caucasian subject, all
other patients were Asian. Approximately half received
CRRT because of sepsis. The ranges of sodium levels in
dysnatremia groups were as follows: mild hyponatremia,
131.1–134.9 mmol/L; moderate to severe hyponatremia,
115.4–131.0 mmol/L; mild hypernatremia, 145.1–
148.4 mmol/L; and moderate to severe hypernatremia,
148.5–166.0 mmol/L. The subjects were followed for a
median of 19 days (4 to 193 days).














Age (years) 63.2 ± 14.94 64.3 ± 15.37 63.9 ± 14.38 60.9 ± 16.15 59.7 ± 17.46 63.2 ± 15.14
Male sex (%) 56.8 61.6 62.3 61.2 56.0 60.5
Enrollment year (%)
2010 15.3 13.4 14.6 14.3 10.0 14.1
2011 29.7 33.0 32.4 16.3 32.0 30.6
2012 33.3 34.8 35.6 46.9 40.0 36.4
2013 21.6 18.8 17.4 22.4 18.0 19.0
Body weight (kg) 62.2 ± 11.56 64.3 ± 13.19 63.6 ± 14.02 65.5 ± 12.48 62.3 ± 10.62 63.5 ± 13.00
Cause of acute kidney
injury (%)*
Sepsis 44.1 † 55.4 49.4 55.1 36.0* 48.9
Surgery 3.6 6.2 11.7 8.2 8.0 8.4
Nephrotoxin 5.4 4.5 8.1 6.1 4.0 6.3
Other 46.8 33.9 30.8 30.6 52.0 36.4
Dialysis dose (mL/kg/hour) 41.9 ± 15.43 47.7 ± 18.61 45.0 ± 16.99 46.2 ± 19.19 41.7 ± 15.90 44.8 ± 17.21
Need for MV (%) 76.6 83.9 85.0 93.9 80.0 83.5
Use of vasoactive drugs (%) 73.0 68.8 72.1 67.3 74.0 71.4
Chronic kidney disease (%) 48.6 46.4 42.5 26.5* 34.0 42.4
Charlson Comorbidity Index † 3.5 ± 2.18 † 3.3 ± 2.25* 2.7 ± 2.13 2.5 ± 2.05 2.5 ± 1.98 2.9 ± 2.17
APACHE II score* 29.6 ± 9.56 28.3 ± 7.91 28.7 ± 8.00 30.6 ± 8.05 32.5 ± 8.15 † 29.3 ± 8.38
Blood findings
Sodium (mmol/L) ‡ 126.6 ± 3.99 ‡ 133.2 ± 1.09 ‡ 139.5 ± 2.74 146.8 ± 0.92 ‡ 154.0 ± 4.81 ‡ 137.6 ± 8.27
Creatinine (mg/dL)* 3.3 ± 2.01 3.7 ± 2.67 † 3.1 ± 1.61 2.8 ± 1.27 2.9 ± 1.69 3.2 ± 1.94
Albumin (g/dL) 2.7 ± 0.57 2.6 ± 0.52 2.7 ± 0.52 2.6 ± 0.51 2.7 ± 0.50 2.7 ± 0.53
Glucose (mg/dL) † 139 (108–190) 147 (116–196) 153 (113–229) 164 (119–222) 191 (134–311) † 152 (115–218)
Urine output (mL/2 hours) 15 (0–70) 20 (0–55) 20 (0–90) 30 (0–118) 28 (4–64) 20 (0–78)
Fluid balance
During 24 h (mL) ‡ 808.3 ± 1527.1861 1069.0 ± 2242.01 1250.7 ± 1971.14 1736.9 ± 2378.86 2772.3 ± 2555.26 ‡ 1304.2 ± 2103.42
During 72 h (mL) † 816.1 ± 2966.11 1036.9 ± 3773.28 999.2 ± 2854.91 1957.4 ± 3839.81 2611.9 ± 2918.75 ‡ 1185.9 ± 3197.57
Onset of dysnatremia (%)
Acute 19.8 34.8 – 77.6 48.0 38.2§
Chronic 61.3 46.4 – 10.2 30.0 43.5
Unknown 18.9 18.8 – 12.2 22.0 18.3
Follow-up duration (days) 13 (4–49)* 19 (4–123) 29 (5–273) 23 (5–434) 9 (3–93)* 19 (4–193)
Comparisons were evaluated using the chi-squared test for categorical variables, the ANOVA test for normally distributed continuous variables (post hoc analysis of LSD
between two groups), and the Kruskal-Wallis test for non-normally distributed continuous variables (Mann–Whitney U test between two groups). The normonatremia
group served as a reference for comparison between two groups
* P < 0.05; † P < 0.01; ‡ P < 0.001; § proportion among dysnatremia group
MV mechanical ventilation, APACHE acute physiology and chronic health evaluation
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The AKI causes differed among sodium groups. Hypo-
natremia groups had higher scores for the Charlson
Comorbidity Index than the normonatremia group. The
moderate to severe hypernatremia group had higher
APACHE II scores than the normonatremia group. The
serum creatinine and albumin levels were similar among
the sodium groups, except for a higher creatinine
level in the mild hyponatremia group. Treatment with
hypertonic saline was used in 8 patients, of whom 7
had moderate to severe hyponatremia and 1 had mild
hyponatremia. Hypotonic saline was used in 13 patients
with mild hypernatremia and 16 patients with moderate
to severe hypernatremia.
Risk of mortality according to sodium level
A total of 57.5 % of the subjects died within 30 days
after starting CRRT. Figure 1 shows the relationship be-
tween baseline sodium level and the predicted probabil-
ity of mortality. The relationship between these variables
appeared to be U-shaped. Based on this observation, we
divided the patients into 5 groups, from hyponatremia
to hypernatremia, and we used the normonatremia group
as the reference for all of the analyses. The crude 30-day
mortality rate was as follows: 50.2 % of those with normo-
natremia, 62.5 % with mild hyponatremia, 65.8 % with
moderate to severe hyponatremia, 51.0 % with mild hyper-
natremia, and 70.0 % with moderate to severe hypernatre-
mia. Kaplan-Meier survival curves (Fig. 2) show that the
survival rates were significantly different (P = 0.016 among
the 5 groups, P = 0.024 among the Fig. 1a groups,
and P = 0.051 among the Fig. 1b groups). The risks
of 30-day mortality according to sodium group are
shown in Table 2. In univariate analysis, both hypo- and
hypernatremia groups, with the exception of the mild
hypernatremia group, had greater ORs for mortality than
the normonatremia group. This trend remained significant
irrespective of covariates' effects. Similar to these results,
the correlation between sodium levels and ORs of mortal-
ity after adjustment for all of the covariates was U-shaped
(Fig. 3). After initiating CRRT, 542 and 457 patients
survived at 24 and 72 h, respectively, and their sodium
levels were included in the subsequent analyses. However,
sodium levels at 24 and 72 h were not associated with
mortality risk (Table 3). Additionally, when adjusted for
the sodium level at baseline, the later sodium levels did
not show a significant correlation with mortality (all
Ps > 0.05).
Sodium correction and mortality
We further analyzed the risk of mortality according
to the change in sodium over 24 or 72 h. The num-
ber of 30-day death cases for each group is shown in
Additional file 2. First, the non-linear relationships
between adjusted ORs for mortality and changes in
sodium levels were explored (Fig. 4). In the groups
with baseline normonatremia or hyponatremia, the
change in sodium over 24 or 72 h did not show an
association with the risk of mortality (Fig. 4a to d). In
the group with baseline hypernatremia (Fig. 4e and f), a
greater decrease in sodium seemed to incur a reduced risk
of mortality. However, this trend was shown only in
the change over 24 h and not over 72 h. In particular,
comparison of mortality rates within three sodium groups,
i.e., normonatremia to normonatremia, hyponatremia
Fig. 1 Non-linear relationship between baseline sodium level and the predicted probability of 30-day mortality. The range area indicates 95 %
confidence intervals. A histogram of the sodium level is also shown
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to hyponatremia, and hypernatremia to hypernatremia,
showed no significant difference (Additional file 3). More-
over, when adjusted for the sodium level at baseline, the
change in sodium levels did not have any significance with
mortality (all Ps > 0.05). These results indicated that
sodium change and correction of dysnatremia did not
change the mortality risk.
Discussion
The present study enrolled patients with specific charac-
teristics (extremely severe AKI and high mortality and
morbidity risks); thus, CRRT was the preferred method
for correction of imbalances in biochemical parameters,
including dysnatremia. The results report for the first
time a correlation between baseline sodium level and
mortality risk in a group undergoing CRRT. However,
the change in sodium, as a marker of sodium correction,
was not associated with mortality risk. These analyses
were helpful in determining whether the correction of
dysnatremia independently reduces mortality in the
presence of several comorbidities.
Dysnatremia is associated with various negative conse-
quences, such as decreased brain function [3], compro-
mised cardiac contractility [4], increased insulin resistance
[14], abnormalities in neuromuscular function [15], cre-
ation of an inflammatory milieu [16], and aggravation of
interstitial edema [17]. Based on these pathologic condi-
tions, it is plausible that dysnatremia contributes to mortal-
ity risk. The present study demonstrated that dysnatremia
predicted mortality in a CRRT cohort. For patients under-
going CRRT, any of the negative conditions driven by
dysnatremia could have contributed to the high mortality.
Similar to the present results with CRRT, dysnatremia
has been associated with high mortality in other several
clinical settings, even with normal kidney function [18].
Most studies adjusted for various comorbidities in their
analyses, thus suggesting an independent association
between sodium and mortality. However, this methodo-
logical approach is not sufficient to draw a final conclu-
sion. Other important data are needed, including whether
each death is directly related to dysnatremia, and whether
the reduction or treatment of dysnatremia itself reduces
mortality. A previous analysis of cases with severe
hyponatremia indicated that deaths were primarily
caused by underlying illness and not by hyponatremia
itself [6]. Furthermore, two thirds of those patients
died, although their sodium levels returned to normal
or near normal ranges. No studies have investigated
Fig. 2 Kaplan-Meier survival curves according to the presence of hyponatremia (a) or hypernatremia (b)
Table 2 Odds ratios for 30-day mortality according to the concentration of serum sodium
Univariate Multivariatea
Group OR (95 % CI) P OR (95 % CI) P
Moderate to severe hypoatremia 1.91 (1.197–3.033) 0.007 3.61 (1.438–9.049) 0.006
Mild hyponatremia 1.65 (1.047–2.610) 0.031 2.45 (1.051–5.705) 0.038
Normonatremia 1 (Reference) 1 (Reference)
Mild hypernatremia 1.03 (0.560–1.908) 0.917 1.06 (0.461–2.438) 0.890
Moderate to severe hypernatremia 2.32 (1.203–4.453) 0.012 2.94 (1.119–7.722) 0.029
aAdjusted for age, sex, enrollment year, weight, cause of acute kidney injury, dialysis dose, need for mechanical ventilation, use of vasoactive drugs, chronic
kidney disease, Charlson Comorbidity Index, APACHE II score, creatinine, albumin, urine output, fluid balance, and onset of dysnatremia
OR odds ratio, CI confidence interval
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the effects of sodium correction on mortality by
using randomization of participants and controlling
for confounders.
In addition to the correlation issue between dysnatre-
mia and mortality, it remains unresolved whether the
correction of sodium could reduce mortality, particularly
in the presence of several comorbidities. A study of this
issue is difficult to conduct. Thus, the present study
might be helpful, despite its observational design, in un-
derstanding the correlation. In contrast to the baseline
level, subsequent sodium levels did not predict mortality
irrespective of timeframe (24 and 72 h), possibly because
of case-mix results, such as the group with baseline
dysnatremia later having normonatremia. Furthermore,
the change in sodium level, including the appropriate
correction of dysnatremia, was not correlated with mor-
tality. These results suggested that sodium level itself
might accurately predict mortality in association with
comorbidities or other related factors; however, the
correction of sodium alone did not contribute to a sur-
vival benefit, particularly under the strong influence of
comorbidities.
The association with mortality may differ for hypona-
tremia and hypernatremia. In the present cohort, mild
hypernatremia was not associated with mortality in
contrast to the results of mild hyponatremia. The dis-
crepancy between the effects of hypo- and hypernatre-
mia has been reported in other observational studies
[19–21]. Each association with mortality could be sensi-
tive to the disease state of study. However, although the
baseline characteristics differ across studies, hyponatre-
mia and hypernatremia should be considered separately
in research, as well as in clinical practice.
Although the present results are informative, this
study has some limitations. First, the observational study
design limits the drawing of conclusions, because of
causality. However, randomized trials of dysnatremia
treatment to determine survival benefit are not feasible,
Fig. 3 Non-linear relationship between baseline sodium level and the odds ratio of 30-day mortality after adjustment for multiple covariates.
The range area indicates 95 % confidence intervals
Table 3 Adjusted odds ratios for 30-day mortality according to sodium level after 24 and 72 h
24-h sodium 72-h sodium
Group OR (95 % CI)a P OR (95 % CI)a P
Moderate to severe hyponatremia 0.81 (0.458–1.418) 0.454 0.89 (0.524–1.528) 0.683
Mild hyponatremia 1.08 (0.629–1.868) 0771 1.08 (0.637–1.825) 0.780
Normonatremia 1 (Reference) 1 (Reference)
Mild hypernatremia 0.90 (0.270–3.027) 0.869 4.69 (0.835–26.302) 0.079
Moderate to severe hypernatremia 6.33 (0.794–50.382) 0.081 3.13 (0.606–16.156) 0.173
aAdjusted for age, sex, enrollment year, weight, cause of acute kidney injury, dialysis dose, need for mechanical ventilation, use of vasoactive drugs, chronic
kidney disease, Charlson Comorbidity Index, APACHE II score, creatinine, albumin, urine output, fluid balance, and onset of dysnatremia
OR odds ratio, CI confidence interval
Han et al. BMC Nephrology  (2016) 17:2 Page 6 of 8
particularly in the presence of comorbidities; thus, the
present results might be helpful in raising awareness
of the correlation between sodium correction and
outcomes. Second, the present cohort of patients who
underwent CRRT is a particular subgroup, thus hindering
the applicability of the conclusions to other populations.
Furthermore, a single therapeutic intervention (i.e., so-
dium correction) might not show a survival benefit
under conditions of high comorbidity rates of CRRT
patients [22]. Third, sodium levels corrected for
Fig. 4 Non-linear relationships between the adjusted odds ratio of 30-day mortality and changes in sodium in the normonatremia (a, b), hyponatremia
(c, d), and hypernatremia (e, f) groups. Figures (a), (c), and (e) show the relationships with changes over 24 h. Figures (b), (d), and (f) show the
relationships with changes over 72 h
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glucose may not be accurate, because the correction
factor may be altered by patient characteristics or
high glucose states [23, 24]. Lastly, we did not re-
trieve important variables (e.g., correction rate of
dysnatremia and neurologic outcomes), which could
affect the overall outcome.
Conclusions
Sodium level at the start of CRRT was a strong predictor of
mortality, as previously observed in other clinical settings.
However, the impact of sodium correction on mortality
was not significant, and would have been weaker in the
presence of multiple comorbidities or severe disease, both
of which have been correlated with dysnatremia. Ran-
domized controlled studies are needed to draw a firm
conclusion, but the present study may be helpful in
understanding the meaning of sodium levels and applying
it in clinical practice.
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